Clinical Trials Directory

Trials / Completed

CompletedNCT04742660

The Effect of Glycyrrhizin on the Occurrence of Postoperative Nausea and Vomiting

The Effect of Administration of Glycyrrhizin During Induction Period on the Occurrence of Postoperative Nausea and Vomiting After Breast Surgery

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
224 (actual)
Sponsor
Konkuk University Medical Center · Academic / Other
Sex
Female
Age
20 Years
Healthy volunteers
Not accepted

Summary

The investigators investigate the association between the administration of glycyrrhizin during induction of general anesthesia and the occurrence of postoperative nausea and vomiting (PONV) in patients undergo breast surgery

Detailed description

Postoperative nausea and vomiting (PONV) is one of a common complication after general anesthesia with 30-50% of incidence, increased up to 80% in high risk group. The risk factors of PONV include women population, the previous history of PONV, motion sickness in usual life, non-smoker, exposure to inhalants, perioperative opioid and laparoscopic surgery. Women population is a strong risk factor of PONV. Although perioperative management of PONV based on a guideline has been done in a lot of medical centers worldwide, the incidence of PONV is still reported relatively high. The main ingredient of Glycyrrhizin is liquorice which has been used as antispasmodics, antiemetics or treatment for gastric ulcer in oriental medicine. Utilizing these effects of liquorice, the investigators investigate whether the addition of glycyrrhzin to conventional antiemetics is effective to decrease the incidence of PONV and improvement of severity of PONV.

Conditions

Interventions

TypeNameDescription
DRUGAmmonium GlycyrrhizinateIn control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin.

Timeline

Start date
2021-05-11
Primary completion
2022-03-08
Completion
2022-03-10
First posted
2021-02-08
Last updated
2024-10-18

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04742660. Inclusion in this directory is not an endorsement.